---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-22-000066"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:06:29.808317+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics and Menarini collaborate for Phase 1b/2 trial of ONA-XR + elacestrant in ER+/PR+ HER2- mBC

## Summary
- Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.
- Menarini supplies elacestrant at no cost; Context sponsors and funds the study.
- Elacestrant Phase 3 showed 30% reduction in risk of progression or death vs SOC in ER+/HER2- mBC.
- 12-month PFS rate: 22% for elacestrant vs 9% for SOC in overall population.
- Preclinical data suggest dual ER and PR blockade may enhance tumor control.

## SEC filing metadata
- accession: 0001842952-22-000066
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/0001842952-22-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/cntx-20220801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-22-000066
- JSON: https://secwatch.observer/filing/0001842952-22-000066.json
- Plain text: https://secwatch.observer/filing/0001842952-22-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.